TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04166162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention Motivational Interviewing (BIMI) Intervention
Description: BIMI is a 15-minute brief interview in person or via video chat with participating youth. The interview will be focused on discussing the impact of drinking alcohol on one's health and how to set personal goals so that alcohol use does not become a problem. A follow up phone or video call at 3 and 6 months post initial interview will also be conducted which will track on the progress of setting and keeping personal goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tomando Buenas Decisiones (TBD) Intervention
Description: The program is adapted from the Guiding Good Choices (GGC) program and will be conducted by a trained facilitator lasting for about 2 hours per session. The program discusses about the best ways to help one's child make good decisions with regards to avoiding alcohol, drugs, and other problem behaviors that may not be healthy to them as well as ways to have good communication and good connections within one's family.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Development Strategy (SDS) Intervention
Description: SDS is a 2 hour broad-focused environmental intervention consisting of short presentations and workshops designed to provide skills and models for positive human interaction between employees to fellow employees, employees to their children and employees to their supervisors.
Study: NCT00187317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training (exercise)
Description: Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
Study: NCT00874614

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultratrace® Iobenguane I131
Description: Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
Study: NCT03988959

Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection of mucoeidermoid carcinoma
Description: Surgical resection parotid with preservation of facial nerve
Study: NCT01611454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XPF thyroid collar
Description: Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard 0.5mm lead equivalent thyroid collar
Description: Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
Study: NCT00821067

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-ribose
Description: A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
Study: NCT00531986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir-Monotherapy
Description: Patients on triple HAART will be switched to LPV/r-monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: Patients will continued their current HAART
Study: NCT01461057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: loading dose of 840 mg, then 420 mg once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
Study: NCT04166162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTC Training Session
Description: BTC training session consists of trainings, discussions and tools focused on community mobilization for the assessment and implementation of evidence-informed preventive interventions addressing community health and behavior problems. Each training session lasts about 4 hours.
Study: NCT01461057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
Study: NCT00187317

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flexibility and relaxation exercise
Description: 30-minute sessions, three times per week for six weeks.
Study: NCT01570179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ideal BW based sugammadex reversal of moderate block
Description: 2 mg/kg sugammadex (based og ideal body weight)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: real body weight based sugammadex reversal of moderate block
Description: 2 mg/kg sugammadex (based on real BW)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: real body weight based sugammadex reversal of deep block
Description: 4 mg/kg sugammadex (based on real BW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ideal body weight based sugammadex reversal of deep block
Description: 4 mg/kg sugammadex (based on ideal BW)
Study: NCT04690296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathetherization approach
Description: real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathetherization approach
Description: real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization
Study: NCT06385912

Intervention type: PROCEDURE
Intervention: lymphadenectomy
Description: Systematic pelvic and para-aortic lymphadenectomy during IDS in lymphadenectomy group
Study: NCT04159116

Intervention type: OTHER
Group type: OTHER
Intervention: Prophylactic suctioning when clinically indicated
Description: Suctioned prophylactically when clinically indicated by copious secretions, coughing, choking or desaturatation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic suctioning when clinically indicated
Description: Suctioned prophylactically when clinically indicated by copious secretions, coughing, choking or desaturatation
Study: NCT03711019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Description: MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RUL-UB ECT
Description: In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bitemporal ECT
Description: Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
Study: NCT01243593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Anesthesia
Description: Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
Study: NCT03088605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1630 Ophthalmic Solution
Description: Bilateral ocular drug administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TOP1630 Ophthalmic Solution
Description: Bilateral ocular drug administration
Study: NCT00302237

Intervention type: DEVICE
Intervention: RX ACCULINK, RX ACCUNET Embolic Protection System
Description: 1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
Study: NCT02061137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod (FTY720)
Description: 0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
Study: NCT02135640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab 60mg
Description: solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab 120 mg
Description: solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution
Study: NCT03854955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iScribes
Description: Device-based scribing service.
Study: NCT04410783

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Nurses and physicians will be engaged regarding the clinical outcome data on the importance of ED-based sedation, and the objectives of the research. Education will include in-services and lectures focused on the importance of sedation protocols on patient outcome. The use of sedation will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based sedation protocols.
Study: NCT01694771

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium
Description: Marketed dose

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Olodaterol
Description: One dose
Study: NCT03072771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: -Blinatumomab is a bispecific T cell engaging antibody

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: -Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: -Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
Study: NCT04604262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterpik
Description: Waterpik dental water jet
Study: NCT03582423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electro-acupuncture
Description: Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
Study: NCT03072771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: -Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: -Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draws
Description: -Day +42, Day + 43, Day +56, and Day +100
Study: NCT03914508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory + Behavioral Weight Loss
Description: BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
Study: NCT04410783

Intervention type: OTHER
Group type: OTHER
Intervention: Standard post intubation sedation practices
Description: Usual care sedation provide in the ED
Study: NCT02859415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mithramycin
Description: Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mithramycin
Description: Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
Study: NCT03705923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
Study: NCT03939910

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.
Description: Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.
Description: Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
Study: NCT03403244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-MR image fusion-guided PTED
Description: patients diagnosed with lumbar disc herniation undergoing US-MR image fusion-guided PTED

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopy-guided PTED
Description: patients diagnosed with lumbar disc herniation undergoing fluoroscopy-guided PTED
Study: NCT03518957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Week 1: Patients will undergo an introductory session where the occupational therapist will assess the general condition and physical fitness of the subjects.~Week 1 to Week 12: Group exercise sessions supervised by a physiotherapist, twice per week, each session lasting 1 hour, with no more than 8 participants in each group exercise session. The exercise regimen for each session will be personally tailored for the subjects, and will include stretching, cardiovascular and strength training, and cooling down exercises.~Week 12 onwards: Patients will receive phone calls- monthly for the first 6 months and then 3 monthly up to the 2-year mark, to encourage them to continue with their exercise regimen at home.
Study: NCT06136338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Women in the experimental group underwent four sessions of mindfulness training. The mindfulness training started at the 28th week of pregnancy for the women, the second training was at the 30th week of pregnancy, the third was at the 32nd week of pregnancy, and the last was at the 34th week of pregnancy, with each session lasting 45 minutes.
Study: NCT02526849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
Study: NCT04507217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, Carboplatin, Pemetrexed
Description: Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT03758677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 30 patients who progressed after EGFR-TKI treatment without T790M mutation will receive apatinib 250mg qd orally combine with chemotherapy , if the patient has a grade 3/4 adverse reaction during such treatment, apatinib should be reduced to 250mg orally once per two days. Chemotherapeutic agents are limited to platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel).
Study: NCT03721679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months
Description: Same as above
Study: NCT02835352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential oils massages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential oils massages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oil massages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oil massages